My research investigates the intersection of epigenetics, aging, and cancer, with a focus on how aberrant epigenetic modifications control cell fate. A central theme of our lab is that aging-like epigenetic alterations create a permissive state for tumorigenesis. Our work aims to elucidate this process and find ways to intervene. Our research activities are structured around three core areas: Identifying Driver Lesions: We use organoid models and multi-omics to discover and functionally validate key epigenetic changes and their target genes that drive both aging and cancer initiation. Dissecting Driving Mechanisms: We explore the upstream causes, such as DNA damage and metabolic stress, that lead to the accumulation of these epigenetic errors over time. Therapeutic Reprogramming: We develop and utilize advanced epigenome editing technologies to correct pathological epigenetic states, with the ultimate goal of reprogramming cell fate for therapeutic benefit in cancer/aging.
Senior Scientist or Principal Investigator
Yunnan University, Kunming, China
01 Mar 2022 - present
Post Doctoral Researcher
Fred Hutchinson Cancer Center, Seattle, USA
01 Jun 2019 - 01 Mar 2022
Post Doctoral Researcher
Johns Hopkins Medicine, Baltimore, USA
01 Dec 2014 - 01 Jun 2019
Research or Laboratory Scientist
Beijing Institute of Genomics, Beijing, China
01 Jun 2009 - 01 Dec 2014